Integra LifeSciences (NASDAQ:IART – Get Free Report) and InspireMD (NYSE:NSPR – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, earnings, dividends, valuation, profitability and analyst recommendations.
Risk & Volatility
Integra LifeSciences has a beta of 1.17, meaning that its stock price is 17% more volatile than the S&P 500. Comparatively, InspireMD has a beta of 1, meaning that its stock price has a similar volatility profile to the S&P 500.
Analyst Ratings
This is a breakdown of recent recommendations for Integra LifeSciences and InspireMD, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Integra LifeSciences | 3 | 4 | 1 | 0 | 1.75 |
| InspireMD | 0 | 0 | 2 | 0 | 3.00 |
Earnings and Valuation
This table compares Integra LifeSciences and InspireMD”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Integra LifeSciences | $1.54 billion | 1.22 | $67.74 million | ($0.09) | -270.64 |
| InspireMD | $6.20 million | 12.22 | -$19.92 million | ($0.75) | -3.87 |
Integra LifeSciences has higher revenue and earnings than InspireMD. Integra LifeSciences is trading at a lower price-to-earnings ratio than InspireMD, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
84.8% of Integra LifeSciences shares are held by institutional investors. Comparatively, 44.8% of InspireMD shares are held by institutional investors. 3.1% of Integra LifeSciences shares are held by company insiders. Comparatively, 29.7% of InspireMD shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Profitability
This table compares Integra LifeSciences and InspireMD’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Integra LifeSciences | -0.42% | 12.35% | 4.82% |
| InspireMD | -413.96% | -69.42% | -57.68% |
Summary
Integra LifeSciences beats InspireMD on 8 of the 14 factors compared between the two stocks.
About Integra LifeSciences
Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services. It also sells instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, the company provides regenerative technology products for the treatment of acute wounds; and surgical tissue repair products for hernia, tendon, peripheral nerve repair and protection. Further, it offers skin and wound repair, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.
About InspireMD
InspireMD, Inc., a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions. InspireMD, Inc. has a strategic agreement with Jacobs Institute to execute an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions. The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.
Receive News & Ratings for Integra LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.
